28

j.med. chem. 1992,35,28-38

structure-antigastrin activity relationships of new
(r)-4-benzamido-5-oxopentanoic
acid derivatives
francesco makovec,* walter peris, laura revel, roberto giovanetti, laura mennuni, and lucio c. rovati
rotta research laboratorium, 20052 monza, milan, italy. received april 26, 1991
new (r)-cbenzamid~50xopentanoic
acid derivatives were synthesized by a stereoconservative procedure and evaluated
in vitro for their capacity to inhibit the binding of [1251](bh)-cck-8to either rat peripheral ( xxxg352xxx ) or central
( xxxg353xxx ) cck receptors, or the binding of [3h]pentagastrinto rabbit gastric glands, as well as to inhibit, in vivo,
the acid secretion induced by  xxxd2873xxx  infusion in the perfused rat stomach. the parent compound of this series
(lorglumide) is the f i i t nonpeptidic, potent and selective antagonist of the  xxxg352xxx . chemical manipulations
of the structure of lorglumide led to the discovery of selective antagonists of the cck-blgastrin receptors.
structure-activity relationships are discussed. some of these new derivatives exhibit different affinities with rabbit
gastric gland cells and rat cortex membranes, suggesting that the stomach  xxxg353xxx  (arbitrarily termed cck-b1
receptor) is not as closely related to the cck central receptor (termed cck-b2) as previously hypothesized. the
antigastrin activity of the most potent compound of the series, le. (r)-4-(3,5-dichlorobenzamido)-5-(8-azaspiro[4.5]decan-8-yl)-5-oxopentanoic
acid (compound 28,cr 2194)was further evaluated in vivo: in the first hour after
administration the compound inhibits acid secretion induced by  xxxd2873xxx  infusion, in both cat and dog (in the
cat with gastric fistula and in the dog with heidenhain pouch), with id,s (mg/kg) of 15.5 (iv) (cat), 8.7 (iv) (dog)
and 24.2 (oral) (heidenhain dog). the characteristics of cr 2194,that is, the selectivity for the  xxxg353xxx ,
the simple nonpeptidic molecular structure, and the activity after oral administration, indicate that this compound
is a useful tool in the study of the biological effects of gastrin and a potential agent for diagnostic or therapeutic
use.

the gastrointestinal polypeptide hormones gastrin and
cholecystokinin (cck) are closely related chemically, both
having a common terminal pentapeptide amide sequence,
but they exhibit different biological effects on their target
tissues. for instance, in vivo, gastrin is a potent stimulant
of acid gastric secretion and a very weak stimulant of
pancreatic enzyme release,' while cck is the main hormonal regulator of gallbladder contractility and of pancreatic enzyme secretion.2 more recently it was demonstrated that cck is also widely distributed in the brain
and it was hypothesized that it may function as a neurotransmitter or neuromodulator in the central nervous
system (cns).3s4 the peripheral actions of cck are
mediated by a receptor subtype termed  xxxg352xxx , while the
central actions are mainly mediated by the subtype receptor termed  xxxg353xxx , for which the minimum agonist
ligand requirement is tetragastrin (cck-4h5 a third
receptor subtype, which appears to be closely related to
the  xxxg353xxx  type, is the stomach  xxxg353xxx .6
d,l-4-[ (3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid (lorglumide, cr 1409) is the
fmt nonpeptidic, potent, competitive, and specific  xxxg352xxx 
antagonist, with low afffity with the  xxxg353xxx  receptor, and
is ineffective, even when administered in subtoxic doses,
as an inhibitor of gastric secretion induced by  xxxd2873xxx 
in the rat.7r8

(1) stening, g. f.; grossman, m. i. gastrin-related peptides as
stimulant of pancreatic and gastric secretion. am. j.physiol. 1969,217,262-266.
(2) jorpes, j. e.;mutt, v. secretion, cholecystokinin, pancreozimine and gastrin; springer verlag: new york, 1973; xxxd1100xxx -79.
(3) dockray, g. j.; hutchison, r. a.; harris, j. b.; gregory, r. a.;
runswick, m. j. isolation, structure and biological activity of
two cholecystokinin octapeptides from sheep brain. nature
1978,274,711-713.
(4) rehfeld, j. f. neuronal cholecystokinin: one or multiple
transmitters? j. neurochem. 1985,44,1-10.
(5) steigerwalt, r. w.; williams, j. a. binding specificity of the
mouse cerebral cortex receptor for small cholecystochinin
peptides. regul. pept. 1984,8, 51-59.
(6) beinfeld, m. c. cholecystokinin in the central nervous system: a minireview. neuropeptides 1983,3,411.

scheme 1." synthesis of compounds 1-62 of table i
coobn

coobn

i
chz
i
chz
i

+ hrj

i

-

ch2

2

chp
1

1

i

chnhcoobn

i

yhnhcoobn
cooh

cor,
63a-y

cooh

cooh

i
ch2
i
ch2
i

chnhp
i

bor,
64sy

+ r2cocl

3

i

chz
1

chp

i

chnhcorp
i
cor,
1-62

"reagents: (1)et3n, etococl; (2)hz,10% pd on c; (3)naoh. bn = benzyl.

recently several potent and specific  xxxg353xxx  antagonists
have been discovered, for example, compounds l-365,2609
or a-methyltryptophan derivatives (ci-988).'o
the aim of our investigation was to explore the possibility that appropriate chemical manipulations of the
structure of lorglumide could lead to new molecular entities
(7) makovec, f.;chisg, r.; bani, m.; revel, l.; setnikar, i.; rovati, l. a. new glutamic and aspartic derivatives with potent
cck-antagonisticactivity. eur. j.med. chem. 1986,21,9-20.
(8) makovec, f.;chisg, r.; bani, m.; revel, l.; rovati, l. c.;
rovati, l. a. differentiation of central and peripheral cholecistokinin receptors by new glutaramic acid derivatives
with cholecystokinin-antagonist activity. arzneim.-forsch.
drug res. 1986,36,98-102.
(9) lotti, v. j.; chang, r. s. a new potent and selective nonpeptide gastrin antagonist and brain cholecystokinin receptor ( xxxg353xxx ) ligand: l-365,260.eur. j. pharm. 1989,162,
273-280.
(10) horwell, d. c.; hughes, j.; hunter, j. c.; pritchard, m. c.;
richardson, r. s.; roberta, e.; woodruff, g. n. rationally
designed 'dipeptoid" analogues of cck a-methyltryptophan
derivatives as highly selective and orally active gastrin and
 xxxg353xxx  antagonists with potent anxiolytic properties. j.
med. chem. 1991,34,404-414.

0022-262319211835-0028$03.00/0 0 1992 american chemical society

new (r)-4-bentamido-5-oxopentanoicacid derivatives

exhibiting potent and selective antagonist activities on
 xxxg353xxx  and gastrin receptors.
chemistry
since it has been demonstrated that the cck-antagonist
activity of lorglumide is stereospecific and due essentially
to the r form,ll we have utilized in the synthesis of these
new derivatives a method (illustrated by scheme i) that
allows retention of the configuration of  xxxd2431xxx .
therefore n-cbz-y-benzylglutamic acid (d or l) is condensed with the amine of formula rih to obtain intermediate 63(a-y). the cbz and benzyl groups are removed
together by reacting 63 dissolved in methanol with hz
under room conditions in the presence of a catalytical
amount of palladium on charcoal. the resultant amino
acid 64(a-y) is then converted to the final product (1-62)
by acylation under schotten-baumann conditions with
equivalent quantities of the appropriate acyl chloride of
formula rzcoc1.
the physicochemical characteristics of the new 4benzamido-5-oxopentanoicacid derivatives are given in
table i.

results and discussion
the results obtained from binding and gastrin antagonism are presented in table 11.
initially we synthesized a homologous series of linear
(c4-c7) alkyl secondary amides of n-benzoyl-d-glutamic
acid, unsubstituted or with mono- and disubstituted chloro
derivatives of the aromatic ring (compounds 1-7). among
these derivatives the 3-chloro compound displayed the
highest anti-gastrin activity in vivo in the perfused rat
stomach (ed,, = 36 mg/kg), whereas, contrary to the sar
in the corresponding lorglumide cck-antagonists series,
the 3,4-dichloro substitution (compound 5) does not increase the activity over that of the unsubstituted aromatic
ring. the introduction in r1 of an alkyl branched substituent at a distance of not less than three carbon atoms
from the amidic nitrogen (compounds 8-19) increases the
antigastrinic activity in vivo.
among these compounds the best substitution was obtained when r1 was a (aminobutyl)-3,3-dimethylgroup and
rz was 3-chloro or 3,5-dichlorophenyl(compounds 10 and
12), both showing an edb0in vivo of 16 mg/kg.
it is worthy to note the complete loss of activity of
compound 20, carrying in r1 a branched chain only two
carbon atoms from the amidic nitrogen.
the introduction in r1 of secondary cyclic (c6-clo size)
amides (compounds 21-25) produces compounds with mild
antigastrin activity. in order to exclude the hypothesis that
the antigastrin activity of this series of 4-benzamido-5oxopentanoic acid derivatives is linked to the presence in
corl of a secondary amido group, a corl tertiary amide
was synthesized in which r1 was a 4,4-dimethylpiperidin-l-yl group and r2a 3-chlorophenyl group. this
compound also exhibited a mild anti-gastrin activity in vivo
(compound 26, ed5,, = 30 mg/kg).
because of this encouraging result, a series of cor1
tertiary amides was synthesized in which the amino group
was an azaspirobicyclo group consisting of not more than
10 carbon atoms and having a maximum length of about
6 a and a maximum width of about 3 a (compounds
27-49).

journal of medicinal chemistry, 1992, vol. 35, no. 1 29

the best anti-gastrin activity in vivo in this series of
derivatives is obtained when r1 is the 8-azaspiro[4.5]decan-8-yl group (compounds 27-42) and among such compounds the compounds in which r2 is 3-chloro or 3,5-dichlorophenyl, showing an ed50 of 15 and 11 mg/kg, respectively (compounds 27 and 28). the introduction of
other halogen substituents in rz such as 2,3-dichloro,
3,4-dichloro, 3-br, or 3-cf3 groups is less favorable. the
same happens with the introduction in rz of alkyl or
alkoxy groups such as 3-me, 3,5-mez,3-et, 4-ipr, and 3och3 (compounds 31-35) as well as with the introduction
of bulky groups such as 2-naphthyl, 3-quinolinyl, and 2indolyl (compounds 40-42) or especially with the introduction of electron-withdrawinggroups such as 3-no2and
3-cn (compounds 36 and 37). less effective are also the
compounds in which r1 is the group 2-azaspiro[4.4]nonan-2-yl (compound 47), 2-azaspiro[4.5]decan-2-yl(compounds 48 and 49), or 3-azaspiro[5.5]undecan-3-yl(compounds 43-46).
good anti-gastrin activity in vivo is obtained when r1
is also a decahydroisoquinolin-2-ylgroup (compound 50)
or a l-(aminoethyl)-2-(lâ€™-adamantyl)group (compounds
51 and 52) and in which r2 is a 3-chloro- or 3,5-dichlorophenyl group. however, the secondary corl amides in
which r1 is 3-aminospiro[5.5]undecaneor 2-aminodecahydronaphthalene (compounds 53-55) are all ineffective,
probably because the r1 group is, in this case, too bulky
or because the spatial arrangement of the r1 moiety is not
suitable for interaction with the hydrophobic receptor
surface.
as in the series of lorglumide  xxxg352xxx  antagonists, with
these new gastrin antagonists the activity is also stereospecific and attributable essentially to the r configuration.
in fact the s enantiomers (compounds 56-60) are all poorly
effective or ineffective in comparison with the corresponding r enantiomers (compounds 10,27-29, and 51).
the situation is different with regard to the affinity with
the peripheral  xxxg352xxx  (binding to the rat pancreatic acini). generally, the corl tertiary amides are
much more effective than the corresponding secondary
amides and higher activity is achieved when r1 is a 3azaspiro[5.5]decan-3-y1group and rz is a 3,4-dichlorophenyl, 2-naphthyl, or 3-quinolinyl group (compounds
44-46).
these compounds are in fact very effective, displaying
an ic50of 0.4-0.6 pm, that is about 10 times higher than
that exhibited by the two di-n-pentyl corl amides ( r ) lorglumide and cr 179512(compounds 61 and 62).
the most potent in vivo  xxxg353xxx  antagonists of the series, for example compounds 10,12,27,28, and 52, are, on
the other hand, very weak  xxxg352xxx  antagonists, all being
about 200-2000 times less potent than the specific  xxxg352xxx 
antagonist (r)-lorglumide.
with regard to the affinity with the central  xxxg353xxx 
receptor (binding to rat brain cortex) the situation is, once
again, different.
some of the most potent in vivo  xxxd2873xxx  antagonists, for example compounds 28 and 52, show a high affinity (ic,, = 0.6 and 0.3 nm,respectively) with the  xxxg353xxx 
receptor, but not higher than that exhibited by compound
45, which is inactive in vivo as an anti-gastrin, or by the
most potent  xxxg352xxx  antagonist of the lorglumide series,
i.e. compound 62, which is completely ineffective on the
same model in vivo. furthermore, compounds 10 and 12,

~

(11) makovec, f.;bani, m.; cereda, r.; chis@, r.; pacini, m. a.;
revel, l.; rovati, l. a.; rovati, l. c.; setnikar, i. pharmacological properties of lorglumide as a member of a new class
of cholecystokinin antagonists. arzneim-forsch. drug.res.
1987,37,11,1265-1268.

(12) kerwin, j. f.;nadzan, a. m.; kopecka, h.; chun we1 lin;
miller, t.; witte, b.; burt,s. hybrid cholecystokinin (cck)
antagonists new implications in the design and modification
of cck antagonists. j. med. chem. 1989,32,739-742.

makouec et al.

30 journal of medicinal chemistry, 1992, vol. 35, no. 1

table i. physical properties of (r)-4-benzamido-5-oxopentanoic
acid derivatives (1-62) prepared by scheme i
hoocch2ch2chcorj

i

"cor,

optical"
%
rotation, overall
compd
r1
r2
mp, "c recryst solvent
deg
yield
formula
anal.
1
3-clcsh.j
154  xxxd2400xxx /h,o 1:2
+22.8b
48
c16h21c1n204
c, h, n
butylamino
128  xxxd2400xxx /h70 1:2
+33.2b
55
c,,h7an.,0a
pentylamino
2
112
 xxxd2400xxx /h;o 1:2
+29.1b
52
pentylamino
3
123  xxxd2400xxx /hzo 1:2
+22.8b
50
pentylamino
4
162 mecn
+17.2'
55
pentylamino
5
44
128  xxxd2400xxx /hzo 1:2
+21.8'
hexylamino
6
135  xxxd2400xxx /h20 1:2
+29.6'
43
heptylamino
7
102 etoh/h20 1:2
+24.0'
47
(3-methylbuty1)amino
8
132  xxxd2400xxx /hzo 1:3
+37.2b
57
(3,3-dimethylbutyl)amino
9
132 etoh/h20 1:l
+21.7'
51
(3,3-dimethylbutyl)amino
10
139 etoh/h20 1:l
+19.3'
48
11
(3,3-dimethylbutyl)amino
+24.0'
140 etoh/hzo 1:l
53
(3,3-dimethylbutyl)amino
12
+14.0'
154 etoh/h20 1:2
54
(3,3-dimethylbutyl)amino
13
+18.4'
160 etoh/h20 1:l
58
(3,3-dimethylbutyl)aino
14
202 etoh/hzo 1:l
-8.4
45
(3,3-dimethylbutyl)amino
15
155 etoh/h20 1:l
+14.7'
37
(4,4-dimethylpentyl)amino
16'
-14.0
184 etoh/h20 1:1
40
(4,4-dimethylpentyl)amino
17
131 etoh/h20 112
+16.6'
(3-ethyl-3-methylpentyl)amino
40
18
115 etoh/hzo 1:l
+13.3'
38
(3,3-diethylpentyl)amino
19
85 etoh/h20 1:l
(2-ethylhexy1)amino
+15.7'
20
43
-2.4
145 etoh/h20 1:1
cycloheptylamino
21
52
135 mecn
+40.0'
cyclooctylamino
47
22
124 mecn
cyclodecylamino
-4.8
32
23
133 mecn
(4,4-dimethylcyclohexyl)amino
+23.6'
44
24
154 mecn
(4,4-diethylcyclohexyl)amino
+17.5'
25
39
4,4-dimethylpiperidin-l-y1
85 mecn
-20.8'
26
50
150 mecn
8-azaspiro[4.5]decan-8-yl
-17.0
27
60
186 mecn/meoh 6:l -17.4
8-azaspiro[4.5]decan-8-yl
28
61
151 mecn
-22.0
8-azaspiro[4.5]decan-8-yl
29
68
167 mecn
8-azaspiro[4.5]decan-8-yl
-26.1'
30
63
150 mecn
8-azaspiro[4.5]decan-8-yl
-17.1
31
53
120 mecn
-14.9
8-azaspiro[4.5]decan-8-y1
32
48
185 etoh/h20 1:l
-17.2
8-azaspiro[4.5]decan-8-yl
33
41
158 mecn
-23.1
8-azaspiro[4.5]decan-8-yl
34
48
116 mecn
8-azaspiro[4.5]decan-8-yl
-15.8
35
36
183 mecn
8-azaspiro[4.5]decan-8-yl
-16.6
36
53
155 mecn
8-azaspiro[4.5]decan-8-yl
-20.1
37
45
146 mecn
8-azaspiro[4.5]decan-8-yl
-14.9
45
38
123 mecn
8-azaspiro[4.5]decan-8-yl
-14.5
39
39
141 mecn
8-azaspiro[4.5]decan-8-yl
-40.6
44
40
105 mecn/h20 5:l
8-azaspiro[4.5]decan-8-yl
-33.6
41
43
109 mecn
8-azaspiro[4.5]decan-8-yl
-39.8
42
23
95 mecn
43
3-azaspiro[5.5]undecan-3-yl
-16.3
55
107 mecn
3-azaspiro[5.5]undecan-3-y1
44
-25.5
52
176 etoh/h20 2:1
3-azaspiro[5.5]undecan-3-yl
-36.0
57
45
123 etoh/h20 2:5
-31.6
3-azaspiro[5.5]undecan-3-yl
46
50
io mecn/h,o 4:l
-14.7
2-azaspiro[4.4]nonan-2-y1
47
45
89 mecn/et20 4 1
2-azaspiro[4.5]decan-2-yl
-16.8
48
54
113 mecn
2-azaspiro[4.5]decan-2-yl
-13.8
49
56
84 mecn
decahydroisoquinolin-2-yl
-24.0b
50
56
187 mecn/meoh 4 1
[2 4 1-adamantyl)ethyl]amino
+8.4'
58
51
[2 4 1-adamantyl)ethyl]amino
182
mecn/h,o 5:l
+8.9'
55
52
146 mecn
-6.6
spiro[5.5]undecyl-3-amino
59
53
158 mecn
-6.6
spiro[5.5]undecyl-3-amino
57
54
83  xxxd2400xxx /h20 1:2
decahydronaphthalenyl-2-amino
+13.4'
55
31
131 etoh/h20 1:l
(3,3-dimethylbutyl)amino
-20.5*
56'
50
140 mecn
57e
8-azaspiro[4.5]decan-8-yl
+16.9
56
190 mecn
58'
+16.6
60
8-azaspiro[4.5]decan-8-y1
151 mecn
+23.0
8-azaspiro[4.5]decan-8-yl
59'
66
187 mecn/meoh 4:l
[2 4 1-adamantyl)ethyl]amino
60'
58
-8.0'
dipentylamino
611
3,4-cl&h3
114 i-pr ether
+17.09
64
c;;h;;c12n204
c; h; n
62h dipentylamino
2-naphthyl
86 etoh/h20 1:2
+11.09
68
c26h36n204
c, h, n
o [ a i z 5 in meoh (3%). [.iz5 in chc13 (3%). 'compound 16 was isolated as the calcium salt.
calcd, 6.97; found, 6.85. 'compounds
56-60 are enantiomers of the s series synthetized for the sake of comparison. fcr 1456 [(it)-lorglumide]: see ref 11. g [a]25in etoh (2.5%).
cr 1795 rotta patent, european application 87830442.7 and ref 13.

'

though having high antigastrin activity in vivo, exhibit only
a low affinity with the central cck-breceptor in vitro.
in order to try to clarify these conflicting results, the
activity of the most significant among the above-mentioned

compounds was evaluated for [3h] xxxd2873xxx  receptor
binding to rabbit gastric glands.
this model gave us the highest specific binding and
therefore was preferred to models using other species, such

new (r)-4-benzamido-5-oxopentanoicacid derivatives

journal of medicinal chemistry, 1992, vol. 35,no. i 31

table 11. biological activities of (r)-4-benzamido-5-oxopentanoic
acid derivatives (1-62)

icw,li,' pm
a/bz
1dw,b~~
 xxxg352xxx 
 xxxg353xxx  (b2)
ratio
mg/kg
in8 (>loo)
50.6 (39-65.5)
64 (55-75)
in (5100)'
96.0 (71-130)
70 (56-87)
36 (24-55)
2.2
30.3 (20.8-44)
66.5 (40-110)
49
0.9
31.3
36.2 (32.8-39.9)
10.2 (7.4-14)
0.8
62
8.6 (5.1-14.6)
3.7
21.5 (17.8-26)
38 (24-60)
80.0
in (>loo)
28.0 (14-56)
in (>75)
in (>loo)
35.3 (29.5-42.2)
35 (30-42)
48.5 (39.2-60)
40 (29-56)
in (>loo)
10.1 (4.6-22)
9.0
16 (13-20)
90.5 (68-120)
40
2.9 (2.1-4)
11
in (>loo)
20.4
16 (12-22)
3.6 (3.1-4.2)
12
73.5
46
6.1
3.1 (1.1-8.7)
18.8 (15.8-22.2)
13
2.3 (1.1-4.8)
25 (19-33)
5.7
13.0 (8.2-20.6)
14
23 (16-34)
1.2 (0.2-7.7)
18.6
15
22.3 (17.6-28.2)
3.2 (2.1-4.9)
20 (15-26)
8.7
27.9
16
1.6 (0.7-3.5)
24 (18-32)
0.2
0.3 (0.1-1)
17
20 (9-45)
5.8
1.9 (1.6-2.3)
11.1 (6.2-20)
18
21 (16-28)
0.9 (0.4-2.5)
8.9
8.0 (4.8-13.4)
19
in (>50)
10.2 (6.1-17)
0.7
6.8 (3.3-14)
20
20.8 (15-28.8)
36 (32-42)
3.9
80.3
21
7.0 (6.1-8)
33
8.6
60.0
22
1.0 (0.3-3)
40 (22-72)
28.9
28.9 (16.0-52.3)
23
5.8 (4.8-7)
23 (20-26)
in (>loo)
24
7.7
22 (18-28)
3.3 (1.8-6.2)
25.5 (19.8-32.8)
25
30 (26-35)
7.8
8.0 (4.3-15)
62.5 (40.9-95.5)
26
9.2
15 (13-18)
1.2 (0.5-2.7)
11.0 (8.6-14.1)
27
22.5
11 (8-15)
0.6 (0.4-0.8)
13.5 (10-18.2)
28
2.6
30 (18-51)
0.5 (0.2-0.9)
1.3 (0.7-2.4)
29
26.0
28
0.8 (0.3-2.2)
20.8 (14.1-30.6)
30
4.1
39
16.3 (10.3-25.7)
67.5
31
4.5
52
16.1 (12.8-20.2)
72.2
32
31 (17-56)
2.5
19.0 (12.8-28)
48.2
33
10.1
31 (24-40)
2.7 (1.2-6.1)
27.3 (22.2-33.4)
34
35 (29-42)
16.5 (5.8-47)
in (>loo)
35
67 (26-171)
in (>40)
in (>loo)
36
66
in (>40)
93.5
37
23 (15-36)
1.8
10.5 (6.2-18)
19.2
38
28 (20-39)
2.0
6.2 (5.3-7.3)
12.5 (8.3-18.8)
39
31 (22-44)
6.6
0.3 (0.1-0.5)
2.0 (1.3-3)
40
0.6
in (>50)
2.3 (0.5-11)
1.3 (0.8-2.2)
41
9.5
33 (25-44)
0.4 (0.2-1.1)
3.8 (2.6-5.5)
42
7.9
33 (26-43)
0.8 (0.4-1.6)
6.3 (3.6-10.9)
43
in (>50)
0.4 (0.2-0.6)
1.0
0.4 (0.2-0.7)
44
3.8
0.2 (0.1-0.3)
3.0
0.6 (0.4-0.9)
45
41
0.5
0.8 (0.4-1.5)
0.4 (0.2-0.8)
46
28 (23-34)
8.1 (5.0-13.1)
3.1
25.2 (15.9-40)
47
38
3.7
3.8 (3.4-4.3)
14.0 (9-21.7)
48
30 (23-38)
14.6
0.7 (0.4-1.2)
10.2 (7.5-13.8)
49
21 (12-36)
38.6
2.3 (1.3-4.2)
88.8
50
22 (11-44)
83.2
0.4 (0.3-0.6)
33.3 (27.2-40.8)
51
17 (14-21)
109.3
0.3 (0.1-0.8)
32.8 (19.0-58)
52
in (>50)
4.5
7.8 (5.5-11)
35.0
53
in (>50)
4.6
6.0 (4.4-8.2)
27.3 (19.6-38.1)
54
12.1
in (>50)
1.9 (1.1-3.4)
23.0 (17.7-29.9)
55
55
44.0 (29-66.6)
in (>loo)
56d
in (>50)
5.8 (2.4-14)
6.9
40.2
57d
12.8
47
3.0 (1.9-4.7)
38.4 (25.3-58.3)
5gd
2.3 (1.8-3)
4.6
in (>50)
10.5 (7.1-15.6)
59d
52
2.8 (2-3.9)
23.5
65.8
60d
in (>50)
3.0 (1.9-4.8)
0.02
0.05 (0.03-0.09)
61e
in (>50)
0.06
0.5 (0.2-1.5)
0.03 (0.02-0.05)
62'
0.5
1.0 (0.6-1.6) nm
0.5 (0.2-1.2) nm
cck-8
257.4
1750 (1434-2135) nm
6.8 (5.6-8.3) nm
- xxxd2873xxx 
a ic,:
mmdisplacing concentration and p = 0.05 fiducial limits required to inhibit by 50% the specific binding of 25 pm [1261](bh)-cck-8 in rat pancreatic acini ( xxxg352xxx ) and rat brain cortex ( xxxg353xxx  or b2). *icm: compound dose in mg/kg iv (bolus) and p = 0.05 fiducial
limits required to inhibit by 50% in the perfused rat stomach the acid secretion induced by 30 pg/kg per h of  xxxd2873xxx  infusion. 'values
without fiducial limits were obtained from not more than two separate testa. dsee footnote e of table i. ecompound 61 or (r)-lorglumide.
/see footnote h of table i. #in = inactive.
compd
1
2
3
4
5
6
7
8
9
10

as guinea pig or rat. the results obtained, reported in
table iii, may be accounted for by the difference of species
employed, but in general a good match with the results
observed in vivo (on the inhibition of  xxxd2873xxx  stimulated acid gastric secretion in the rat) was obtained. in

fact compound 28 is the most potent gastrin inhibitor of
the series in both in vivo and in vitro models; in addition,
compounds 10, 12, and 27 display important anti-gastrin
activity in vivo as well as on gastric glands in vitro.
compound 45 and (r)-lorglumide,which are barely ef-

32 journal of medicinal chemistry, 1992, vol. 35,no.1

makooec et al.

table 111. comparison of binding inhibition of 4-benzamido-5-oxopentanoicacid derivatives in different models (icw, rm)
['zsi]cck-8a
[sh]pentagasttin:b
rat
rat
rabbit
pancreatic
brain cortex
gastric glands
ai?,'
b,i?s
compd
acini ( xxxg352xxx )
( xxxg353xxx  or b,)
( xxxg353xxx  or b,)
ratio
ratio
10
90.5
10.1
2.2 (1.4-3.5)
9.0
0.2
12
73.5
3.6
2.0 (1.1-3.5)
20.4
0.5
27
11.0
1.2
0.8 (o.l%z.o)
9.2
0.7
28
13.5
0.6
0.2 (0.14.4)
22.5
0.3
45
0.6
0.2
23.0 (15.8-33.5)
3.0
115
51
33.3
0.4
8.3 (5.7-12.0)
83.2
20.8
52
32.8
0.3
8.1 (5.4-12.2)
109.3
27.0
(r)-lorglumide
0.05
3.0
25.0 (18.5-33.1)
0.02
8.3
 xxxd2873xxx 
11.54 nm
6.8 nm
6 (4.4-8.1) nm
257.4
0.9
values drawn from table 11. * icm: rm displacing concentration and p = 0.05 fiducial limit against 6.7 nm [3hlpentagastrin.

fective or totally ineffective in the inhibition of gastric
secretion, exhibit, as expected, only slight activity on this
in vitro model.
by examining the ratios a/b, and b,/b, of table i11
(the stomach  xxxg353xxx  and the cck central receptor are termed by us  xxxg353xxx , and  xxxg353xxx ,, respectively), it is possible to observe that compounds 10,12,27,
and 28 have the equivalent property of exhibiting 10-20
times higher affinity for the cck-bzcentral receptor in
comparison with the peripheral  xxxg352xxx , whereas
the affinity for the  xxxg353xxx , peripheral  xxxg353xxx  is
even higher than that for the central cck-b2, also with
the same order of magnitude.
conversely, compound 45 shows a high affinity for the
central cck-bp receptor as well as for the peripheral
 xxxg352xxx , whereas it is, as already stated, almost
ineffective in inhibiting gastrin binding to the  xxxg353xxx ,
peripheral  xxxg353xxx  (b1/b2 ratio is 115). furthermore the adamantyl derivatives 51 and 52, exhibit a
much higher affiiity with the  xxxg353xxx , receptor than that
displayed on inhibiting the binding on both  xxxg352xxx  and
 xxxd2873xxx   xxxg353xxx , peripheral receptors.
taken together, these results are further evidence of
what was already hypothesized by other^,'^ that at least
three receptor subtypea for the cck/gastrin system exist
and that the stomach  xxxg353xxx  ( xxxg353xxx ,) may not
be so closely related to the central  xxxg353xxx  (or cck-b2)
receptor as previously hypothesized.
the presence or the lack of a second c-5 straight alkyl
chain in corl seems to be, therefore, a major factor in
dwecting these 4-bemamido-5-oxopentanoicacid derivatives to antagonism with  xxxg352xxx  rather than  xxxg353xxx , or
cck-b2 receptors. the relative inactivity of (r)-lorglumide in inhibiting the  xxxd2873xxx  binding on the putative
 xxxg353xxx , recsptor, together with the lack of any anti-pastrin
activity in vivo, has led us to s u p p m that the 4-benzamido-5-oxodi-n-alkylpentanoicacid derivatives could
compete at the receptor site with the 26-28 cck moiety
rather than with the terminal pentapeptide (29-33) of
cck. on the other hand, the 4lmmmid~5-oxopentanoic
acid derivatives in which cor, is either a secondary amido
group having a bulky substituent not less than two unsubstituted carbon units from amido group or a tertiary
amido group of the optimum size of a bicyclo spiro group
are able to compete especially with the terminal pentapeptide sequence shared by both cck and gastrin. thii
speculation reflects the experimental results obtained with
the two series of pentanoic acid derivatives, i.e. the lor(13) cberner, j. k; sutliff, v. e.; grybwski, d. m.; jenaen, r. t.;
gardner. j. d. functionally distinct receptors for cholecystokinin and gastrin of dispersed chief cells from guinea pig
stomach. am. j. physiol. 1988,251,g1516155.

figure 1. computer superposition of 10 on tetragastrin cck(3&33) showing carbxyl group, aromatic ring, and methionine
and tert-butyl alkyl chain matching: red, tetragastrin; blue,
compound 10.

glumide series and this new  xxxg353xxx  antagonist series, but
evidently other explanations for such binding selectivities
are also poasible.
to further understand the structure-activity relationships between the terminal cck tetrapeptide (trp-metasp-phenh,) (c30-c33) and the 4-benzamido-5-oxopentanoic acid derivatives cck/gastrin inhibitors, a computer-assisted conformational analysis was carried out in
order to determine the low-energy conformation of both
the agonist and its antagonists. for the paradigmatic
example the structure of compound 10 was fitted to the
low-energy structure for tetragastrin, taking the carboxylic
acid of both molecules as an anchor group and allowing
other groups of compound 10 to orient independently
within the space that the computer graphics gave a p
proximately as the beat superposition of the two st.ructurea
however, for both molecules the minimized structure energy, that is, 29.28 kcal/mol for compound 10 (coded cr
2093) and 60.23 kcal/mol for tetragastrin, was maintained.
as shown in figure 1,it seems that once we have fmed
the superposition of both carboxylic groups of the two
molecules and the superposition of the 3-chlo10benzamido
moiety of compound 10 with the region of space of terminal
phenylalaninamide group of tetragastrin, we can see that
the cor, 4,4-dimethylbutylamide side chainof 10 exhibits

new (r)-4-benzamido-5-oxopentanoicacid derivatives

journal of medicinal chemistry, 1992, vol. 35,no. 1 38

figure 4. molecular packing in the triclinic unit cell of 10.
...c16

figure 2. computer superposition of (r)-lorglumideon tetragastrin cck(3c-33) showing carboxyl group and aromatic ring
matching and overlay lacking between methionine and n-pentyl
groups: red, tetragastrin; blue, (r)-lorglumide.

q&o~31

o(21

f

w 3. a perspective view of 10 showing the atomic numbering

scheme.
an extensive overlap with the hydrophobic methionine
moisly. one might therefore speculate that r1could serve
as an additional anchor group for interaction with a second
hydrophobic region of the  xxxg353xxx . in contrast,
the superpositioning of (r)-lorglumide with cck(30-33)
by matching both the carboxyl group and the phenyl ring
of the two structures does not allow to successfully overlay
the residual hydrophobic moieties, i.e. the methionine and
n-pentyl groups (figure 2).
tovalidate the results of computer conformational
analysis, an x-ray structure study of compounds 10 and
(r)-lorglumide was performed. in figure 3 an arbitrary
projection of the molecule of compound 10 with the atomic
numbering scheme is shown.
a small deviation from planarity is present in the
chlorobenzamido group (plane i) where c14 lies 0.02 a
from the leasbsquares plane. no significant deviation from
planarity is detected on the c1, n1, 01, c13 group (plane
il), while the group c6.04, n2, c2 shows a small distortion
from planarity (plane 111).
planes i and 11form an angle of 17.35o, while planes 11
and i11 form an angle of 74.73'. a gauche conformation
is present along the sequence c z c 3 4 4 4 5 (torsion angle
of 64.7"). all packing distances are within the expected
range and bond angles; bond lengths and torsion angles
selected to describe the geometry of the molecule by the

c16("ii-.i

c:..l f"

cls'i..j:.,

'?f.,m4
%.l

(
jc1
@ o

,.-,.'

ijcn'
figure 5. a perspective view of (r)-lorglumide showing the
atomic numbering scheme. dashed atom belong to disordered
moieties.

figure 6. molecular packing in the monoclinic unit cell of
(r)-lorglumide. dashed lines show the disordered n-pentyl 8equences.
x-ray method do not differ significantly from those calculated by the computer conformational analysis and used
above in superposition drawings.
the molecular packing diagram of compound 10 in the
unit cell is illustrated in figure 4.
figure 5 shows an arbitrary projection of the molecule
of (r)-lorglumidewhere disorder affecting the two pentyl

makouec et al.

34 journal of medicinal chemistry, 1992, vol. 35, no. 1

table iv. comparison of antigastrinic activity of (r)-4-(3,5-dichlorobenzamido)-5-(8-azaspiro[4.5]decan-8-yl)-5-oxopentanoic
acid
(compound 28) in different models in vivo
 xxxd2873xxx 
dose,
 xxxd1281xxx ,: mg/kg (fiducial limits)
route of
rg/kg per h
0-60 min
6c-120 min
administration
perfused rat stomach*
30
11.0 (8-15)
iv (bolus)
6
15.5 (8-30)
44.2 (24-85)
iv (bolus)
secretion in gastric fistula cat model
secretion in gastric fistula dog model
3
8.7 (4-19)
28.8 (16-50)
iv (bolus)
secretion in heidenhain pouch dog model
6
24.2 (19-31)
33.6 (24-46)
oral
a idso: compound dose in mg/kg and p = 0.05 fiducial limits required to inhibit by 50% the acid secretion induced by the given dose of
 xxxd2873xxx  infusion in the different conscious animals. for protocol, see in vivo evaluation in the experimental section under biological
methods. value drawn from table 11.

evaluation of its anti-gastrin activity in vivo on two other
animal species.
in dogs with chronic gastric fistulas, the compound was
given by iv bolus in a dose range of 5-30 mg/kg, against
a fixed submaximal stimulation of gastric acid secretion
induced by a 2-h iv infusion of  xxxd2873xxx  (3 pglkg per
h). compound 28 dose dependently antagonizes the gastric
acid output induced by  xxxd2873xxx  infusion, with an edm
of 8.7 mg/kg in the first hour after bolus administration
and an ed,,, of 28.8 mg/kg in the second hour.
from the above-mentioned results it seems likely that
compound 28 has the same antigastrin potency in both rat
and dog. in this connection, it is interesting to note that
the most potent nonpeptidic  xxxg353xxx  antagonist discovered
up to now (i.e. the benzodiazepine derivatives l-365,260)
was reported to be much less effective in the dog, that in
other tested animals species, such as the mouse, rat, and
guinea-pig? these results lead us to suppose a qualitative
difference between the two antigastrin series.
in the heidenhein pouch dog model, the compound,
given in a dose range of 10-40 mg/kg intragastrically, dose
dependently reduces the gastric acid output induced by
a 2-h iv infusion of 6 pg/kg per h of  xxxd2873xxx . at 40
mg/kg the reduction is about 70% in both the first and
second hour collection period after its oral administration.
the calculated id50are in this case 24.2 and 33.6 mg/kg,
respectively.
in cats with chronic gastric fistulas the compound exhibits the same pattern of activity as in the dog. under
a 2-h 6 pg/kg per h iv  xxxd2873xxx  stimulation, the gastric
acid output is reduced by 50% at the dose of 15 mg/kg
in the first hour after iv bolus and at the dose of 44 mg/kg
in the second hour collection period.
the results obtained are shown in figure 8 and in table
iv.
conclusions
compound 28 (coded cr 2194) is the most potent
 xxxg353xxx  antagonist among the newly described class of

,yoh

figure 7. compound 28 (cr 2194).

aliphatic sequences is noted. no significant deviation from
planarity is detected in the dichlorobenzoyl group (plane
i) nor in the c1, n1, 01, c17 (plane 11)and c6, 04, n2,
c2, (plane 111) groups. planes i and i1 form an angle of
69o while planes i1 and i11 form an angle of 97.4o.
in figure 6 part of the crystal packing of (r)-lorglumide
is shown, supporting the statement that disorder in the
alkylic sequences is due to the poor interaction between
these moieties and neighboring groups.
it is worthy to note that in the lorglumide structure the
carbon atoms (cll-cl6) of the two pentyl chains, which
are mainly in all-trans state, are about 9 a apart, so that
the overall shape of the molecule is strongly characterized
by the presence of three distinct hydrophobic moieties.
this seems to be the main difference with the molecular
structure of compound 10, in which the presence of only
two hydrophobic moieties of suitable dimensions, apart
from the carboxylic group, seems to be more favorable for
the interaction with the  xxxg353xxx .
compound 28 (figure 7), the most potent cck/gastrin
receptor antagonist of this series, was chosen for further
100
80
90

i
0

a

5

10

doses

20

25

(mg/kg)

15

iv

30

c

0

10

doses

20

30

(mg/kg)

40

os

50

0 3

12.5

doses

25

37.5

(mg/kg)

50

iv

figure 8. effects of 28 (cr 2194) on dose-response curves in antagonizing gastrin-stimulated acid secretion in different models: (a)
dog with gastric fistula;  xxxd2873xxx  infusion dose of 3 pg/kg per h; (b) dog with heidenhain pouch;  xxxd2873xxx  infusion dose of
6 pg/kg per h; (c) cat with gastric fistula;  xxxd2873xxx  infusion dose 6 pg/kg per h. in abscissa given doses (bolus) of 28 by different
routes of administration. each point represents the mean of three different experiments. m: effects in the first hour (0-60min) from
bolus administration of 28. 0: effects in the second hour (60-120 min) from bolus administration of 28.

new (r)-4-benzamido-5-oxopentanoic
acid derivatives

journal of medicinal chemistry, 1992, vol. 35, no. 1 35

biological tests. male adult sprague-dawley rats, new
zealand white rabbits, beagle dogs, and tabby cats were used.
cck-8 and  xxxd2873xxx  were purchased from peninsula laboratories, ['251](bh)-cck-8(specific activity 2000 ci/mmol) was
from amersham, ultima gold was from packard, [3h] xxxd2873xxx 
(specific activity 31 ci/mmol) was from nen, rabbit  xxxg124xxx  and bovine  xxxg124xxx  (bsa) were from merck
(darmstadt, germany), bacitracin was from serva (heidelberg,
germany), soybean  xxxd207xxx  (sbti) was from pl biochemicals (st. goar, germany), crude collagenase was from
boehringer (mannheim, germany), and hepes [4-(2-hydroxyethyl)- 1-piperazineethanesulfonicacid], egta [ethylenebis(oxyethylenenitri1o)tetraacetic acid], and dtt (m-dithiothreitol)
were from sigma.
the compounds under investigation were dissolved as sodium
salt in distilled water for the in vitro studies, or in saline for the
in vivo studies. estimated concentrations or doses at 50% effect
(icboor idm) and their p = 0.05 fiducial limits were calculated
from the regression line of the percentage of maximum effect,
discarding the 6% tails, on the logarithm of the concentration
or of the dose.
(1) antisecretory activity in rats. fasted (24 h) male rats
anesthetized with urethane were used. gastric acid secretion was
determined in the perfused rat stomach according to the method
of ghosh and schild14with slight modifications. the substances
under investigation were administered by iv bolus in triplicate,
in at least three doses after 60 rnin from the beginning of  xxxd2873xxx  infusion. the inhibition (%) of gastric acid secretion
is calculated from the values of total acid output collected before
(fmt 60 min of  xxxd2873xxx  infusion) and after the administration
of the substances (second 60 min of  xxxd2873xxx  infusion).
(2) antisecretory activity in dogs w i t h a heidenhain
pouch. fasted (24 h) conscious heidenhain pouched dogs15 were
used. gastric acid secretion was stimulated by  xxxd2873xxx 
continuous infusion at a dose of 6 pg/kg per h into the cefalic
vein. gastric juice was collected for 2 h, at 15-min intervals
following the start of the  xxxd2873xxx  infusion. total acid output
was measured by titrating 1ml of gastric juice to ph 7 with 0.1
n naoh. compound 28 a t four dose levels and in triplicate ( n
= 12) or placebo was administered orally, 30 min before  xxxd2873xxx  infusion. total 15-min hcl output was plotted against
the time of infusion; the area under the curve (auc) was calculated and the gastric acid antisecretory activity of the compound
was calculated as the percentage of the auc of the control dogs.
(3) antisecretory activity in dogs with gastric fistula.
conscious dogs with a gastric fistula16were used. the method
of gastric acid stimulation is the same as that described above,
with the exception of the dose of  xxxd2873xxx , which was 3 pg/kg
per h, while the period of collection was 3 h. compound 28 a t
three dose levels and in triplicate (n = 9) or saline was given
intravenously 45 min following the start of the  xxxd2873xxx  infusion, when the gastric acid stimulation had reached maximal
levels. total 15-min hcl output was plotted against the time of
infusion; the area under the curve after drug administration was

calculated and the gastric acid antisecretory activity of the compound was calculated as the percentage of the auc of the control
dogs.
(4) antisecretory activity in cats with gastric fistula.
conscious cats with a gastric fistula were used after 2 4 h fasting.
the method of the gastric acid stimulation is the same as described
above in 2. gastric juice was collected for 3 h,  xxxd1891xxx -min intervals
following the start of the  xxxd2873xxx  infusion. compound 28
at four dose levels and in triplicate ( n = 12) or saline was given
intravenously 40 rnin following the start of  xxxd2873xxx  infusion,
when the gastric acid stimulation had reached maximum levels.
total 10-min hcl output was plotted against the time of infusion;
the area under the curve after drug administration was calculated
and the gastric acid antisecretory activity of the compounds was
calculated as the percentage of the auc of the control cats.
binding studies.  xxxg352xxx  binding assays were carried
out on rat pancreas by the collagenase method previously de5~ribed.l~briefly, tissue (about 5 g) was extensively minced and
dispersed in 30 vol of krebs-henseleit buffer (khb) (118 mm
 xxxg2020xxx ,25 mm nahc03, 4.7 mm kc1,1.2 mm nah2p04, 0.1 mm
cac12,14 mm glucose, and 0.1 mg/ml sbti 1% bsa) adjusted
to ph 7.4. to this medium, continuously shaken and gassed with
95% 02-5%co2, was added 0.5 mg/ml crude collagenase. the
resulting suspension was filtered with nylon mesh (320 pm),
layered over khb containing 4% bsa, 0.5 mm cac12,and 0.1
mg/ml sbti, and centrifuged for 5 min a t 13%. the final
resulting pellet was suspended in 10 vol of hepes-ringer ph 7.4
buffer (118mm nacl, 10 mm hepes, 1.13 mm mgc12, 1.28 mm
cac12,and 1% bsa). this preparation gave a final concentration
of 1-3 x lo7 cells/ml (assessed by light microscope with the aid
of a neuebauer chamber), which was diluted with binding assay
to about 5 x io6 cells/ml.
 xxxg353xxx  receptor binding aways were carried out on membranes
of rat cerebral cortex, as previously des~ribed.'~the tissue (about
800 mg) was homogenized in ice-cold 20 mm hepes (ph 6.5) and
centrifuged twice at 50000g. the washed final pellet was resuspended in 50 vol of binding away buffer (20 mm hepes, 5 mm
mgcl,, 360 mm  xxxg2020xxx ,15 mm kc1,l mm egta, and 0.2 mg/ml
bacitracin). protein concentration was determined by using the
method of bradford,'8 using bsa as the standard. this procedure
gave about 1pg of protein/pl.  xxxd2873xxx  (cck-b1) receptor
binding assays were carried out on isolated glands from the rabbit
gastric mucosa according to the method of berglindhlswith minor
modifications. briefly, the fundic mucosa was separated from
muscular and submucosal layers, weighed (ca. 6 g), and then
minced into small pieces and transferred to 50 ml of collagenase
solution (130 mm  xxxg2020xxx ,12 mm nahc03, 3 mm nah2p04, 3 mm
na2hp04,3 mm k2hp04,2 mm mgs04, 1mm cac12,10 mg/l
phenol red, 0.2% glucose, and 1% rabbit  xxxg124xxx , ph 7.4)
containing 1 mg/ml of collegenase.
the suspension was continuously gassed with 100% o2 at 37
"c, gently stirred for 20-25 min, and then filtered through nylon
mesh (320 pm). free cells were removed by gravity sedimentation
for 15 min and the glands were washed free from isolated cells
and collagenase three times with buffer binding solution (132 mm
 xxxg2020xxx ,5.4 mm kcl, 5 mm na2hp04,1 mm nah2p04, 1.2 mm
mgso,, 0.2% rabbit  xxxg124xxx , 0.2% glucose, and 0.5 mm
d?t, ph 7.4). this procedure gave about 7-8 ml of sedimentated
glands with 90% viability (trypan blue exclusion method). the
suspension was diluted in buffer binding to obtain about 375 mg
wet weight/ml.
binding conditions for both  xxxg352xxx  and cck-b2binding assays
were the same. cortical membranes or acini (400 pl), tracer
(55000 dpm/tube), and displacing agents were incubated in a
0.5-ml total volume in polypropylene tubes for 30 rnin a t 37 oc.

(14) ghosh, n. m.; schild, h. 0. continuous recording of acid
gastric secretion in the rat. br. j. pharmacol. 1958, 13,
54-61.
(15) andersson, s. inhibitory effecb of hydrochloric acid in the
duodenum on gastrin-stimulated gastric secretion in heidenhain pouch dogs. acta physiol. scand. 1960,50,105-112.
(16) andersson, s.;olbe, s. gastric acid secretory responses to
gastrin and histamine in dogs before and after vagal denervation on the gastric pouch. acta physiol. scand. 1964,60,
51-56.

(17) innis, r.b.; snyder, s.h. distinct cholecystokinin receptors
in brain and pancreas. proc. natl. acad. sci. u.s.a. 1980,77,
6917-6921.
(18) bradford, m. m. a rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. anal. biochem. 1976,72,
248-254.
(19) berglindh, t.;obrink, k. j. a method for preparing isolated
glands from the rabbit gastric mucosa. acta physiol. scand.
1976,96,150-159.

4-benzamido-5-oxopentanoicacid derivatives by its ability
to block  xxxd2873xxx -stimulated acid secretion in several
models. it has a simple nonpeptidic molecular structure
and it is pharmacologically effective even after oral administration. these properties indicate that this compound could be a useful tool in the study of the biological
effects of gastrin and a potential agent for diagnostic or
therapeutic uses in man.
experimental section

36 journal of medicinal chemistry, 1992, vol. 35, no. 1

makovec et al.

table v. physical properties of compounds 63a-y prepared by path 1, scheme i
bn00cch2ch2chcor1

i

nhcoobn

compd
63a
63b
63c
63d
63e
63f
63g
63h
63i
63j
63k
631
63m
63n
630
6 3 ~
63q
63r
63s
63t
63u
63v
63w
63x
6 3 ~
a benzene/ethyl

r1
butylamino
(3-methylbuty1)amino
(3,3-dimethylbutyl)amino
pentylamino
(4,4-dimethylpentyl)amino
(3-ethyl-3-methylpenty1)amino
(3,3-diethylpentyl)amino
hexylamino
(2-ethylhexy1)amino
heptylamino
(4,4-dimethylcyclohexyl)amino
(4,4-diethylcyclohexyl)amino
cycloheptylamino
cyclooctylamino
cyclodecylamino
decahydronaphthalen-2-ylamino
spiro[5.5]undecyl-3-amino
[2-(l-adamantyl)ethyl]amino

mp, "c
124
143
106
108

recryst solvent
etoh/i-pr20 1:3
 xxxd2400xxx /i-pr20 1:3
etoh/hzo 2:l
 xxxd2400xxx /i-pr20 1:4

ri"
0.38
0.50

0.78'
0.42
0.83'

ws'
ws'
0.88'
0.91'
oil
101
 xxxd2400xxx /i-pr20 1:4
0.46
110
 xxxd2400xxx /i-pr20 1:4
0.71
100
 xxxd2400xxx /i-pr20 1:4
0.51
84
i-pr20
0.57
0.58
oil
153
etoh/i-pr20 1:l
0.49'
120
 xxxd2400xxx /i-pr20 4:l
0.48
81
i-pr20
0.70
123
 xxxd2400xxx /i-przo 1:3
0.65
0.66
oil
77
etoh/i-pr20 1:l
0.66
4,4-dimethylpiperidin-l-y1
oil
0.51
0.48
decahydroisoquinolin-2-yl
oil
2-azaspiro[4.4]nonan-2-yl
oil
0.39
0.41
2-azaspiro[4.5]decan-2-yl
oil
0.59
8-azaspiro[4.5]decan-8-yl
oil
0.54
3-azaspiro[5.5]undecan-3-y1
oil
0.7gd
oil
dipentylamino
acetate 7:3. methylene chloride/ethanol 91. ws: waxy solid. chloroform/ethyl

'

then 1ml of ice-cold assay buffer was added, and the tubes were
centrifuged at 12500g. the supernatant was eliminated and the
radioactivity associated with the pellet measured in a packard
5000 y-counter (80% efficiency). nonspecific binding was estimated as 5 pm ccks (on average, 30% for  xxxg352xxx  and 45% for
cck-b2 binding studies).
binding conditions for  xxxd2873xxx  binding assay were similar
except that 220 pl of gastric glands suspension (about 0.5 mg
protein/tube) was incubated with tracer (115000 dpm/tube) and
displacing agent for 15 min at 37 "c in a fiial volume of 0.25 ml.
the centrifuged pellet was digested in 1 ml of 1 n naoh and
the radioactivity measured in a packard tri-carb liquid scintillator spectrometer after dilution with ultima gold (40% efficiency). nonspecific binding was estimated with 0.1 mm  xxxd2873xxx  (on average 50%).
chemistry. the following procedures were adopted 'h nmr
spectra were recorded a t 60 mhz on a varian em360l or at 300
mhz on a bruker cxp-300 instrument; infrared spectra were
recorded on a perkin-elmer 1420 ratio recording ir spectrophotometer with 3700 data station. melting points were determined on a buchi 535 apparatus and are uncorrected. elemental analysis were performed by redox (cologno monzese, mi),
and the analytical results were within &0.4% of the theoretical
values unless otherwise noted. tlc was carried out using merck
silica gel gf254 plates with the following elution systems: a
(1-butanol/acetic acid/water 5:2:2), b (isoamyl alcohol/acetone/water 5:2:1), c (methylene chloride/ethanol 9:1), and d
(benzene/ethyl acetate 7:3). specific rotation was determined
with a jasco dip-370 polarimeter at 589 nm in a 100-mm cell
and at 3 g/100 ml, except where otherwise indicated. the optical
purity of the enantiomers was tested by hplc using a varian
5500 liquid chromatograph, a resolvosil bsa-7 column (macherey-nagel) as stationary phase, and 0.1 m ph 8.0 phosphate
buffer + 5% n-proh as mobile phase. butylamine, 3-methylbutylamine, 3,3-dimethylbutylamine,  xxxd141xxx , hexylamine,
heptylamine, 2-ethylhexylamine, cycloheptylamine, cycloethylamine, cyclodecylamine, decahydroisoquinoline, 3-azaspiro[5.5]undecane, and dipentylamine were purchased from commercial suppliers and were used without further purifications.
4,4-dimethylpentylamine,203-methylethylpentylamine,21 3,3(20) amundsen, l. h.; nelson, l. s. reduction of nitriles to primary amine with lithium aluminium hydride. j. am. chem.
soc.1951, 73, 242-246.

formula
c24h30"205
c25h32n205
c26h34n205
c25h32n205
c27h36n205
c28h38n205
c29h40n205
cz6h34nz05
cz8h38nz05
cnh36nz05
cz8h36nz05

anal.
c, h, n
c, h, n
c, h, n
c, h, n

c, h, n
c, h, n
c, h, n
c, h, n

c30h40n205

c27h34n205
c28h36n205
c3oh4onz05
c30h38n205

c, h, n
c, h, n
c, h, n
c, h, n

c31h40n205

c3zh4onz05

c, h, n

c27h34n205
c29h36n205

c28h34n205
c29h36n205
c29h36n205
c30h38n205

c30h42n205
acetate %l.

diethylpentylamine,21 4,4-dimethylcyclohexylamine,224,4-diethylcyclohexylamine,22 c y c l ~ d e c y l a m i n e , ~4,4-dimethyl~
~ i p e r i d i n e 8-azaspir0[4.5]decane,~~
,~~
2-azaspir0[4.4]nonane,2~
2-azaspir0[4.5]decane,2~2 4 l'-adamant~l)ethylamine,2~3-spiro2-de~ahydronaphthylamine,~'
and n[5.5]~ndecyclamine,~~
cbz-ybenzyl-d-glutamic acidz8were prepared by the cited literature methods. acyl chlorides were synthesized from the
corresponding commercially available acids by refluxing with
thionyl chloride and were purified according to conventional
methods.
(r)-4-[(carbobenzyloxy)amino]-5-[
(3,3-dimethylbutyl)amino]-5-oxopentanoic acid, benzyl ester (63c). t o a mechanically stirred solution of 10 g (26.93 mmol)  xxxd2589xxx -(carbobenzyloxy)(cbz) xxxd2431xxx  5-benzyl ester and 3.83 ml (27.46
mmol) of triethylamine in 50 ml of t h f at -10 "c was added
dropwise 2.62 ml (27.46 mmol) of ethyl chloroformate. stirring
was continued at -10 "c for 15 min and then 3.27 g (32.31 mmol)
of 3,3-dimethylbutylamine was added dropwise at the same
temperature. at the end the stirring was continued for 1 h at
-10 "c and for 3 h a t room temperature. after removal of white
solid by filtration, evaporation of the solvent under reduced
p m u r e left a crude product, an acoet solution which was washed
(21) prout, f. s. unsymmetrical quaternary carbon compounds.
i. the alkylation of ethyl 2-cyano-3-methyl-2-pentanoate
with aliphatic grignard reagent. j. am. chem. soc.
1952,74,

5915-5917.
(22) johnston, t. p.; mccaleb, g. s.; opligen, p. s.; laster, w. r.;
montgomery, j. a. synthesis of potential anticancer agents.
38. n-nitrosoureas. 4. further synthesis and evaluation of
haloethyl derivatives. j. med. chem. 1971, 14, 600-614.
(23) sicher, j.; svoboda, m. stereochemical studies. viii. synthesis of medium and large ring cis- and trans-2-aminocyclanols. chem. listy. 1958,52, 156c-1585.
(24) mcmanus, j. m.; mcfarland, j. w.; gerber, c. f.; mclamore,
w. m.; laubach, g. d. sulfamylurea hypoglycemic agents. i.
synthesis and screening. j. med. chem. 1965, 8, 766-776.
(25) najer, h.; giudicelli, r.; sette, j. bull. soc.
chim., fr. 1964,
10,2572-2581.
(26) bott, k. chem. ber. 1968, 101, 564-73.
(27) pinkus, j. l.; pinkus, g.; cohen, t. a convenient stereospecific synthesis of axial amines in some steroidal decanyl and
cyclohexyl systems. j. org. chem. 1972,27,4356-4360.
(28) hanby, w. e.; waley, s. g.;watson, j. synthetic polypeptides
part 11.  xxxd2431xxx . j . chem. soc.
1950, 3239-3249.

new (r)-4-benzamido-5-oxopentanoic
acid derivatives

journal of medicinal chemistry, 1992, vol. 35, no. 1 37

table vi. physical properties of compounds 64a-y prepared by path 2, scheme i
hoocch~ch~chcori

i

"2
1 4 2 5 ~ ~

compd
r1
mp, "c
64a
butylamino
148
64b
(3-methylbuty1)amino
148
64c
(3.3-dimethvlbutvl)amino
154
pentylamino
138
64d
(4,4-dimethylpentyl)amino
ws'
64e
64f
(3-ethyl-3-methylpenty1)amino
126
117
(3,3-diethylpentyl)amino
64g
135
64h
hexylamino
oil
64i
(2-ethylhexy1)amino
136
64j
heptylamino
(4,4-dimethylcyclohexyl)amino
183
64k
(4,4-diethylcyclohexyl)amino
157
641
169
cycloheptylamino
64m
cyclooctylamino
166
64n
155
cyclodecylamino
640
decahydronaphthalen-2-ylamino
159
6 4 ~
143
spiro[5.5]undec-3-ylamino
64q
170
[2-(l-adamantyl)ethyl]amino
64r
4,4-dimethylpiperidin-l-y1
159
64s
decahydroisoquinolin-2-yl
161
64t
2-azaspiro[4.4]nonan-2-y1
131
64u
2-azaspiro[4.5]decan-2-y1
137
64v
175
8-azaspiro[4.5]decan-&yl
64w
170
3-azaspiro[5.51undecan-3-yl
64s
oil
dipentylamino
6 4 ~
"c = 3,2 n naoh. ' c = 3, meoh. e ws: waxy solid.
with 2 n hc1 (50 ml) and water to remove excess unreacted
amine. the organic layer was then washed with cold 0.1 n naoh
(50 ml) and water. the solvent was dried and removed under
reduced preasure and the residue was precipitated with diisopropyl
ether, fdtered, and dried to give 9.67 g (79%) of 63c. an analytical
sample was obtained by recrystallizationfrom ethanol/water 21:
mp 106 "c; tlc c (r,0.78); 'h nmr (cdc13)0.9 (s,9 h, t-bu),
1.15-1.65 (m, 2 h, ch,-t-bu), 1.85-2.3 (m, 2 h, c(n-cbz)chz),
2.3-2.7 (m, 2 h,ch2coobn),3-3.5 (m, 2 h,nch2),4.1-4.65 (m,
1 h, chn), 5.1 ( s , 4 h, ch,ph), 6.2 (d, 1 h, cnhcoobn, j =
8 hz), 6.6-7 (m, 1 h, conh), 7.35 ppm (8, 10 h, ph); ir (kbr)
3303,3051,2956, 1739,1693, 1649,1540 cm-'; [cyiz5~
= +8.04" (c
= 3; chc13). anal. (c26h34n205)
c, h, n. with this procedure
compounds 63a-y, shown in table v, were synthesized.
(r)-l-amino-e[ (3,3-dimethylbutyl)amho]-5-oxopentanoic
acid (64c). a solution of 8 g (17.6 mmol) of 63c in 60 ml of
methanol and 10 ml of water containing 0.2 g of 10% palladium
on activated charcoal was stirred for 2 h under hydrogen a t
atmospheric pressure and room temperature. the solution was
filtered and evaporated to dryness under reduced pressure. the
solid crude product was treated with acetone and collected on
a filter (3.3 g, 81% yield). an analytical sample was obtained with
a crystallization from water: mp 154 "c; tlc a (r, 0.70); 'h
nmr (dilute naod) 0.9 (s, 9 h, t-bu), 1.15-1.65 (m, 2 h,
ch,-t-bu), 1.65-2 (m, 2 h, cnchj, 2-2.55 (m, 2 h, ch,cooh),
2.9-3.6 ppm (m, 3 h, ch and nch,); ir (kbr) 3394,3249,3068,
2955,1683,1555,1397,1265cm-'; [ c ~ ] =
~ ~-25.9'
d (c = 3; meoh).
anal. (cllh22n203)c, h, n.
with this procedure the compounds 64a-y, shown in table vi,
were synthesized.
(r)-4-(3-chlorobenzamido)-5-[
(3,3-dimethylbutyl)amino]-5-oxopentanoic acid (compound 10 or cr 2093). to
a vigorously stirred solution of 3 g (13.03 mmol) of 64c and 13.68
ml of 1n naoh in 15 ml of water and 20 ml of thf at room
temperature were added simultaneously from two dropping
funnels 13.68 ml of 1 n naoh and 1.75 ml (13.68 mmol) of
3-chlorobenzoyl chloride dissolved in 20 ml of thf. then stirring
was continued for 3 h and f i y , after partial removal of the thf
under vacuum, the solution was acidified to congo red with dilute
hcl. the resulting oil was extracted with acoet; the organic
layer was selectively extracted with 0.1 n naoh until the acoet
was free from 3-chlorobenzoicacid. the solvent was dried and
evaporated to dryness, resulting in a viscous oil which solidified

recryst solvent
me2co/h203:l
me2co/h204:l

deg
-14.2
-21.9'
-25.9'
-9.2

me2co/h204 1
me2co/h204 1
me2co/h204 1

-16.7'
-17.1'
-9.3

me2co/h203:l
me2co/h201:l
h2o
me2co/h201:l
h2o
me2co/h204:l
meco/h20 3 1
h2o
h20
me2co/h202:l
h2o
me2co/h204:l
me2co/h204 1
me2co/h203:l
me2co/h201:l

-9.0
-13.6
-11.1

-15.4
-16.0
-19.6b
-17.6'
-11.7
-7.3
-17.2
-8.6
-8.3
-5.6
-10.0
-11.2

formula
cgh18n203

anal.
c, h, n

c10h20n203

cllh22n203
c10h20"203
c12h24n203
c13h26n203
c14h28n203
cllh22n203
c13h26n203

c12h24"203
c13h24n203
c15h28n203
c12h22n203
c13h24n203
c15h28n203

c14h24n203

c13h22n203

c14h24"203
c14h24n203

c15h26n203

c15h30n203
table vii. crystal data for compound 10 and (r)-lorglumide
10
(r)-lorglumide
formula
cl8"25c1n204
czzh3zc1znz04
crystal dimensions (mm) 0.3 x 0.3 x 0.5 0.5 x 0.5 x 0.2
crystal system
triclinic
monoclinic
p1
space group
p21lc
9.148 (2)
12.418 (7)
a, a
10.685 (2)
18.786 (4)
b, 8,
11.347 (2)
12.598 (6)
c, a
(y
107.67" (1)
96.51" (1)
120.2 (4)
b
108.37" (1)
y
v, a3
975
2540
2
z"
4
density calcd, g/cm3
1.261
1.206
intensities (unique)
4522
4731
1964
intensities >3u(1)
2131
rb
6.5
8.9
9.8
6.7
r,,!
" number of formula units in the unit cell. disagreement factors for observed reflections.

'

under petroleum ether. the white solid was filtered to give 3.8
g (80% yield). an analytical sample was obtained by a recrystallization from ethanol/water 1:l: mp 132 o c ; tlc b (r, 0.73);
'h nmr (dmso-$) 0.9 (9 h, s, t-bu), 1.2-1.6 (2 h, m, ch,t-bu),
0.9 (9 h, s, t-bu), 1.2-1.6 (2 h, m, ch,-t-bu), 1.8-2.6 (4 h, m,
chzch2cooh),2.9-3.4 (2 h, m, nchz),4.2-4.7 (1h, m, ch),
7.5-8.1 (5 h, m, c6h4and nh of 3,3-dimethylbutylamide),8.6
(1h, d, j = 8 hz, nhcoph, exchangeable), 12.1 ppm (1h, s,
cooh, exchangeable); ir (kbr) 3291, 3094, 2963, 1732, 1633,
1573,1547,1204,733cm-'; [o!]=d = +21.75' (chc13);optid pul'it!,'
evaluated by hplc was higher than 99%, t r 7.9 min ( t r of s
enantiomer of 10, i.e. compound 56 is 7.0 min). anal. (cl8hz5c1nzo.j c, h, n.
with this procedure compounds 1-62 shown in table i, were
synthesized.
computer-aided design. the software used for superimposition of 10 and (r)-lorglumide on tetragastrin cck (30-33)
was mad (molecular advanced design) (available from aquitaine
systemes, tour elf, la defense, paris, france) and run on an
ibm 6150 with the graphics station ibm 5085. the optimization
of low-energy conforms was conducted by monte carlo-metropolis

j. med. chem. 1992,35, 38-47

38

algorithm, using a dynamic weighting of the randomly chosen
rotation axes to be modified. the starting data set is minimized
using a function that randomly selects the rotation axes. during
the first part of the calculation, the â€œheaviestâ€ rotation axes are
favored, next the â€œlightestâ€ ones (second part), and finally the
â€œheaviestâ€ ones again (third part). one hundred iteractions with
maximums or de less than 0.1 kcal/mol were performed for
optimization, according to newton-raphson.
crystal analysis of 10. a colorless crystal suitable for x-ray
diffraction studies for both compound 10 and (r)-lorglumide,
prepared by slow cooling of an ethyl acetate solution, was mounted
on an enraf-nonius cad-4 diffractometer and irradiated
with monochromatized mo k a radiation using the 8/28 scan
technique. the intensities were correlated for lorentz and polarization factors. the structures were solved by direct methods
with multan-n2â€™ and refined with shelx-7630using blocked
(29) germain, g.; main, p.; woolfson, m. m. application of phase
relations to complex structure 111. optimum use of phase
relations. acta crystallogr. sect. a. 1971, 27, 368-376.

full-matrix least-square refinement. all non-hydrogen atoms were
refined anisotropically,while hydrogen atoms, located by different
fourier maps or by theoretical calculations, were refined isotropically. the main crystal data obtained for both compound
10 and (r)-lorglumide are registered in table vii.

supplementary material available: tables containing the
atomic coordinates, bond distances, bond angles, torsion angles,
and weighted least-square planes through the selected atoms from
x-ray diffraction studies for compound 10 (coded cr 2093) and
(r)-lorglumide, tables containing the atomic coordinates, bond
distances, bond angles, and torsion angles from computer-aided
design for compound 10, (r)-lorglumide, and tetragastrin (39
pages). ordering information is given on any current masthead
page.
(30) sheldrick, g. m. shelx. computer crystallographyproceedings of an international summer school; schenk; henk; 01thof-hazekamp, r., van koningsveld, h., eds.; delft univ.
press: delft, netherlands, 1978; pp 34-42.

synthesis, characterization, and biological evaluation of a novel class of
n - (arylethy1)-n-alkyl-2-(1-pyrrolidiny1)ethylamines: structural requirements
and binding affinity at the q receptor
brian r. de costa,* lilian radesca, lisa di paolo,â€™ and wayne d. bowen*.+
laboratory of medicinal chemistry, national institute of diabetes and digestive and kidney diseases, national institutes of
health, bethesda, maryland 20892, and section of biochemistry, division of biology and medicine, brown university,
providence, rhode island 02912. received april 23, 1991
by synthesizing and testing a part-structure, n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-(
1-pyrrolidiny1)ethylamiie
(3), derived from our previously reported high affinity u receptor ligands (ls,2r)-(-)-n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-(1-pyrrolidinyl)cyclohexylamine[(4-21 and (+)-2, we have identified a novel class of superpotent
(subnanomolar affinity) u ligands specific for the u receptor labeled by [3h]-(+)-3-ppp. when 3 was tested for
its capacity to displace [3h]-(+)-3-pppfrom guinea pig brain membranes, it exhibited a ki of 0.34 nm, which is
better than either of its parent compounds (-)-2 (ki= 1.3 nm) and (+)-2 (ki = 6.0 nm). other compounds related
1-homopiperidiny1)ethylamine (19) exhibited ki = 0.17
to 3 such as n-[2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-(
nm ([3h]-(+)-3-ppp). the determinants for high u receptor affinity of 3 were examined by manipulation of this
structure in a number of different ways. the high efficacy of these compounds for the u receptor, their relative
chemical simplicity and ease of synthesis, and their high degree of selectivity identifies n-[ 2-(3,4-dichlorophenyl)ethyl]-n-methyl-2-(l-pyrrolidinyl)ethylamine
(3) and related compounds as a highly promising base for
determination of the functional role of u receptors as well as the development of novel therapeutic agents.

introduction
u receptors have attracted much attention due to their
ability to bind with significant affinity a number of psychoactive compounds or compounds with other activities
(see ref 1for a review). among these are haloperidol and
other typical n e u r o l e p t i c ~the
, ~ ~dissociative
~
anesthetic
phen~yclidine,~
the antitussive dextromethorphan,5 and
the steroid hormone progesterone.6 though many u ligands bind to other receptors, u sites are distinct from any
known neurotransmitter or  xxxg1603xxx . attempts
to define a functional role(s) for u sites have resulted in
its implication in several physiological and biochemical
processes. among these are (1)regulation of motor behavior and postural tone,â€™-9 (2) negative modulation of the
phosphoinositide response to muscarinic cholinergic
agonists,â€™+l2 (3) regulation of smooth muscle contraction,13-15and (4) neuroprotective activity.16 the ability
of q ligands to affect motor systems and protect from
neuronal damage suggests that selective u compounds may
brown university.

be useful therapeutic agents in the treatment of motor
disorders such as dystonia17 and protection from the
(1) walker, j. m.; bowen, w. d.; walker, f. 0.; matsumoto, r. r.;

(2)

(3)

(4)

(5)

(6)

de costa, b. r.; rice, k. c. sigma receptors: biology and
function. pharmacol. rev. 1990,42,355-402.
su, t.-p. evidence for sigma opioid receptor: binding of
[3h]skf10,047to  xxxd2070xxx -inaccessible sites in guinea pig
brain. j. pharrnacol. exp. ther. 1982,223, 284-290.
tam, s. w.; cook, l. sigma-opiates and certain antipsychotic
drugs mutually inhibit (+)-[3h]skf10,047and [3h]haloperidol
binding in guinea pig brain membranes. r o c . natl. acad. sci.
u.s.a. 1984,81, 56165621.
sircar, r.; nichtenhauser, r.; ieni, j. r.; zukin, s. r. characterization and autoradiographic visualization of (+)-[3h]skf10,047 binding in rat and mouse brain: further evidence
for phencyclidine/â€sigma opiateâ€ receptor commonality. j.
pharmacol. exp. ther. 1986,237,681-688.
klein, m.; paturzo, j. j.; musacchio, j. m. the effects of prototypic sigma ligands on the binding of [3h]dextromethorphan
to guinea pig brain. neurosci. lett. 1989,97, 175-180.
su, t.-p.; london, e. d.; jaffe, j. h. steroid binding at sigma
receptors suggests a link between endocrine, nervous, and immune system. science 1988,240, 210-221.

0022-2623/92/1835-oo38$03.00/00 1992 american chemical society

